Study to test solanezumab's potential in preventing Alzheimer's

01/20/2013 | Washington Times, The

Dr. Reisa Sperling, director of the Alzheimer's disease center at Brigham and Women's Hospital in Boston, will be heading a study that will test an experimental drug from Eli Lilly & Co. called solanezumab. The study, to include 1,000 people with plaque buildup but no signs of dementia, will test whether the drug can prevent the development of Alzheimer's when administered before symptoms manifest. Researchers are also paying close attention to whether the drug can at least hinder the speed of cognitive degeneration.

View Full Article in:

Washington Times, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
FDA/Post Drug Approval Attorney
Quarles & Brady
Washington, DC
Vice President for Product Delivery
National Committee for Quality Assurance
Washington, DC
SENIOR REGULATORY AFFAIRS SPECIALIST - 13000006XJ
Abbott
Oakland, CA
FDA/Device Technology Attorney
Quarles & Brady
Washington, DC
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC